Rokit Healthcare Accelerates U.S. Expansion Roadmap with Fundamental Regenerative Therapy Surpassing Temporary Pain Relief

On June 18, Rokit Healthcare, an artificial intelligence (AI)-based organ regeneration platform company, officially announced that it has completed the registration of a core technology patent related to cartilage regeneration with the United States Patent and Trademark Office (USPTO).

The U.S. patent covers "ultra-personalized hyaline cartilage regeneration therapeutic compositions," signifying that Rokit Healthcare has secured technological independence and global competitiveness for its AI-based cartilage regeneration platform.

A company representative stated, "This is a structurally and fundamentally differentiated cartilage regeneration treatment technology, completely distinct from conventional temporary pain relief treatments." The representative added, "We expect rapid commercialization through our AI hyaline cartilage regeneration platform, which integrates AI analysis, cartilage regeneration bio-ink technology, and bioprinting."

According to U.S. market research firm Credence Research, the U.S. cartilage regeneration market is valued at approximately $2.33 billion as of 2024 and is projected to surpass $3.6 billion by 2032, with a compound annual growth rate (CAGR) of 5.7%. The U.S. cartilage regeneration market is rapidly growing as a high-value-added treatment market, driven by the super-aging population, an increase in sports injuries, and the rise in early diagnosis of knee osteoarthritis.

The company stated, "This patent registration fulfills all scientific, commercial, and legal requirements for the practical development of cartilage regeneration treatment business in the U.S. and other advanced markets." The company added, "We are initiating a full-scale commercialization strategy in the U.S. market, including negotiations with global distribution partners, entry into hospital networks, and expansion of strategic alliances."

In fact, Rokit Healthcare has already demonstrated the global business potential of its cartilage regeneration products through its entry into the South American market, and with this U.S. patent registration as a starting point, it is expected to accelerate its expansion into the world's largest cartilage regeneration market.

Chief Executive Officer Yoo Seokhwan emphasized, "This patent registration is an achievement that demonstrates the structural stability and differentiation of Rokit Healthcare's AI ultra-personalized cartilage regeneration technology in the global market." He added, "As a first mover in the global cartilage regeneration market, we will continue to deliver tangible results in the United States as well."